The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. In clinical studies, combination regimens with CDK4/6 inhibitors consistently double progression-free survival compared to endocrine therapy alone. The impact on overall survival data, however, has been less consistent thus far, with some agents showing a greater benefit than others. This program discusses the real-world survival benefit and tolerability of CDK 4/6 inhibitors in patients with HR+/HER2- breast cancer. Clinicians will gain a broader understanding of how these therapies work in patients and obtain access to a patient education tool that will help inform shared decision-making between patients and providers.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.